Last reviewed · How we verify
Withania somnifera
At a glance
| Generic name | Withania somnifera |
|---|---|
| Sponsor | Sunnybrook Health Sciences Centre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Therapy for Recurrent Ovarian Cancer (PHASE1, PHASE2)
- Ashwagandha for Nighttime Waking (NA)
- Plant Protein With Ashwagandha-Rhodiola for Sleep Quality (NA)
- Effect of Ashwagandha Root Extract on Stress, Anxiety, and Sleep Quality in Adults Experiencing Minority Stress (NA)
- Ashwagandha Supplementation for Prevention of Muscle Damage (NA)
- Supplement Combination on Stress and Sleep (NA)
- Effects of Root Extract Ashwagandha (KSM-66) on Physiological Stress, Perception of Recovery and Muscle Strength in Youth Elite Footballers (NA)
- Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory and Cardiovascular Biomarkers in Healthy, Older Individuals. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Withania somnifera CI brief — competitive landscape report
- Withania somnifera updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI